The SCIENTIFIC VOICE of the ERN ReCONNET MEMBERS
ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products. Talarico et al., 2023. Clin Exp Rheumatol.
The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. Talarico et al., 2022. Clin Exp Rheumatol.
An overlook on the current registries for rare and complex connective tissue diseases and the future scenario of TogethERN ReCONNET. Bandeira et al., 2022. Sec. Rheumatology
The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. Talarico et al., 2021. NaTure RevIews | RheumatOlOgy
An Opportunity to Harmonise the Approach to Patients’ Care Pathways for Rare and Complex Diseases: RarERN Path™. Talarico et al., 2022. Front Health Serv.
RarERN Path: a methodology towards the optimisation of patients’ care pathways in rare and complex diseases developed within the European Reference Networks. Talarico et al., 2020. Orphanet J Rare Dis
Clinical practice guidelines adherence, knowledge and awareness in rare and complex connective tissue diseases across Europe: results from the first ERN ReCONNET survey. Talarico et al., 2020. RMD Open
ERN ReCONNET SUPPLEMENT
The Supplement (Clinical and Experimental Rheumatology, 2022) presents an overview on different and relevant aspects associated to such rare and complex diseases with
a collection of reviews, scientific articles, and case reposts. Below the specific links to the single articles.
Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study. Bozzalla-Cassione et al.
Atypical variants in COL1A1 and COL3A1 associated with classical and vascular Ehlers-Danlos syndrome overlap phenotypes: expanding the clinical phenotype based on additional case reports. Colman et al.
Treatment of relapsing polychondritis: a systematic review. Petitdemange et al.
STATE of the ART on CPGs
The Supplement (BMJ, 2018) presents a short report on the first year of activity of the ERN ReCONNET, ten reviews on clinical practice guidelines of the Diseases covered by the ERN ReCONNET project, and a report on rCTDS Health Economics. This is one of the first results of the collaboration of Healthcare Providers and Patients in the framework of the ERN ReCONNET. Below the specific links to the single articles.
Clinical practice guidelines: the first year of activity of the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET). Marta Mosca and Maurizio Cutolo
IgG4-related disease: state of the art on clinical practice guidelines. Iaccarino et al.